AI assistant
Sending…
Lexaria Bioscience Corp. — Director's Dealing 2023
Feb 27, 2023
34983_dirs_2023-02-27_0758c681-c97a-4c04-99a6-56e34b7a59ed.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2023-02-09
Reporting Person: TURKEL CATHERINE C. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-09 | Common Shares | P | 1500 | $2.8446 | Acquired | 1500 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options | $3.04 | 2027-09-02 | Common Shares (3400) | 3400 | Direct |
| Stock Options | $1.96 | 2027-10-12 | Common Shares (1600) | 5000 | Direct |
More from Lexaria Bioscience Corp.
Interim / Quarterly Report
2026
Apr 13
Director's Dealing
2026
Mar 18
Delisting Announcement
2026
Feb 6
Regulatory Filings
2026
Jan 28
Declaration of Voting Results & Voting Rights Announcements
2026
Jan 28
Capital/Financing Update
2026
Jan 14
Delisting Announcement
2026
Jan 14
Interim / Quarterly Report
2026
Jan 13
Capital/Financing Update
2025
Dec 29
Regulatory Filings
2025
Dec 19